Pourhassan's comment about doubling the number of deaths in the placebo arm was a gross oversimplification used as part of a very simplistic explanation, I think.

Poster Rex has several posts as to how to conduct the statistical analysis of the severe/critical primary endpoint, which is death. I would describe all of those analyses as at least somewhat complicated.

No way anyting is "doubled" except as a way of explaining to the general public that there were approximately twice as many patients in the leronlimab arm as in the placebo arm, I think.